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(57) ABSTRACT 
The isolation and characterization of two protein isoforms 
collected green fluorescent copepods is described herein. The 
new Pontella mimocerami GFP-like isoforms pmimGFP1 
and pmimGFP2 of the present invention are quick to mature 
and rapidly produce a fluorescent signal. The two isoforms 
are very similar in molar extinction coefficients (ME) with 
105,000 M' cm for pmimGFP1 and 103,000 M'cm for 
pmimGFP2, respectively. The relative brightness of these two 
new copepod GFP-like proteins is the highest measured for 
any isolated GFP-like protein. 
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ACTACTCTGCTCAGGTCA ACA ACCACATGCACTTCA AGAGTGCCATCCATCCCAC 
CATGCTCCAGAATGGTGGATCCATGTTCACCTACAGAAAGGTTGAGGAGCTCCAC 
ACACA AACTGAAGTTGGTATTGTTGAGTACCAGCATGTCTTCAA AACTCCAACTG 
CTTTTGCT 
FIG. 818 
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ACACA AACTGAAGTTGGTATTGTTGACGTACCAGCATGTCTTCAA AACTCCAACTG 
CTTTTGCT 
FIG. 9TB 
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1. 
SOLATION AND CHARACTERIZATION OF 
NOVEL GREEN FLUORESCENT PROTENS 
FROM COPEPODS 
STATEMENT OF FEDERALLY FUNDED 
RESEARCH 
This invention was made with U.S. Government support 
under Contract No. R01 GMO78247 awarded by the NIH. The 
government has certain rights in this invention. 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is the National Stage of International 
Application No. PCT/US2010/026755, filed Mar. 10, 2010, 
which claims the benefit of U.S. Provisional Application No. 
61/162,112 filed Mar. 20, 2009, which are incorporated 
herein by reference in its entirety. 
INCORPORATION-BY-REFERENCE OF 
MATERIALS FILED ON COMPACT DISC 
None. 
TECHNICAL FIELD OF THE INVENTION 
The present invention relates in general to the field of green 
fluorescent proteins (GFPs), and more particularly to the iso 
lation and characterization of two novel GFP isoforms from a 
copepod species. 
BACKGROUND ART 
Without limiting the scope of the invention, its background 
is described in connection with the isolation and character 
ization of green fluorescent proteins (GFPs) from a marine 
copepod. 
Green fluorescent proteins (GFPs) were originally isolated 
from the jellyfish Aequorea victoria and have a green fluo 
rescence when exposed to blue light. WIPO patent WO/1995/ 
007643 issued to Chalfirand Prasher (1995) discloses a GFP 
from the jellyfish A. Victoria that retained its fluorescent 
properties when expressed in heterologous cells. 
U.S. Pat. No. 5,625,048 issued to Tsien and Heim (1997) 
teaches modifications in the sequence of Aequorea wild-type 
GFP to provide products having markedly different excitation 
and emission spectra from corresponding products from 
wild-type GFP. The modifications described included alter 
ation in the ratio of the two main excitation peaks, fluores 
cence at shorter wavelengths, and the presence of only a 
single excitation peak. 
US Patent Publication No. 20040086968 (Evans, 2004) 
describes mutants of the GFP of Aequorea victoria. Specifi 
cally disclosed are nucleic acid molecules encoding mutant 
GFPs, the mutant GFPs encoded by these nucleic acid mol 
ecules, vectors and host cells comprising these nucleic acid 
molecules, and kits comprising one or more of the above as 
components. The invention also provided methods for pro 
ducing these mutant GFPs. The fluorescence of these mutants 
is observable using fluorescein optics, making the mutant 
proteins of the present invention available for use in tech 
niques such as fluorescence microscopy and flow cytometry 
using standard FITC filter sets. 
DISCLOSURE OF THE INVENTION 
The present invention describes novel green fluorescent 














sion libraries were synthesized from the isolated mRNA to 
yield the genes responsible for the green fluorescence in the 
Pontellid copepods, similar to the GFP first isolated from the 
jellyfish Aequorea victoria. 
In one embodiment the present invention discloses an iso 
lated nucleic acid molecule comprising a nucleotide sequence 
that is at least 95% homologous to a SEQ. ID NO. 2 or to a 
SEQ. ID NO. 4. The nucleotide sequence described in the 
preferred embodiment is cloned from one or more RNA mol 
ecules isolated from one or more marine species, comprising 
of one or more Pontellids, jellyfish species, hydrozoans, 
anthozoans, corals, copepods, arthropods, crustaceans, chor 
dates, cephalocordates, or any combinations thereof. In one 
aspect the nucleotide sequence encodes one or more func 
tional proteins, and said nucleotide sequence is at least 95.96, 
97.98 or 99% identical to a SEQ. ID NO. 2 or to a SEQ. ID 
NO.: 4. 
In another aspect the one or more functional proteins com 
prise one or more green fluorescent proteins, having a molar 
extinction coefficient of at least 100,000 M'cm and a 
quantum yield of at least 0.90. In yet another aspect the one or 
more green fluorescent proteins have an absorbance maxi 
mum between 480-490 nm and an emission maximum 
between 500-511 nm. 
In another embodiment the present invention describes an 
isolated protein molecule comprising an amino acid 
sequence, wherein the amino acid sequence is at least 95% 
similar to a SEQ. ID NO.: 1 or to a SEQ. ID NO. 3. In one 
aspect the protein molecule is a green fluorescent protein 
having a molar extinction coefficient of at least 100,000 
M'cm' and a quantum yield ofat least 0.90. In an additional 
aspect the protein molecule comprises an amino acid 
sequence that is at least 95, 96, 97.98 or 99% identical to a 
SEQ. ID NO.: 1 or to a SEQ. ID NO. 3. In another aspect the 
protein molecule has an absorbance maximum between 480 
490 nm and an emission maximum between 500-511 nm. In 
yet another aspect the protein molecule is isolated from one or 
more marine species, comprising of one or more Pontellids, 
jellyfish species, hydrozoans, anthozoans, corals, copepods, 
arthropods, crustaceans, chordates, cephalocordates, or any 
combinations thereof. 
In yet another embodiment the present invention describes 
an expression vector comprising one or more nucleic acid 
sequences, wherein the nucleic acid sequence encodes one or 
more functional proteins. In one aspect the one or more 
nucleic acid sequences are at least 95% homologous to a 
SEQ. ID NO. 2 or to a SEQ. ID NO. 4. In another aspect the 
one or more encoded functional proteins have an amino acid 
sequence that is at least 95% similar to a SEQ. ID NO.: 1 or to 
a SEQ. ID NO. 3. In yet another aspect the one or more 
nucleic acid sequences are cloned from one or more RNA 
molecules isolated from one or more marine species compris 
ing one or more Pontellids, jellyfish species, hydrozoans, 
anthozoans, corals, copepods, arthropods, crustaceans, chor 
dates, cephalocordates, or any combinations thereof. In an 
additional aspect the one or more encoded functional proteins 
comprise one or more green fluorescent proteins having a 
molar extinction coefficient of at least 100,000 M'cm' and 
a quantum yield of at least 0.90, having an absorbance maxi 
mum between 480-490 nm and an emission maximum 
between 500-511 nm. 
In a further embodiment the present invention discloses a 
host cell comprising a nucleic acid sequence wherein the 
nucleic acid sequence is at least 95% homologous to a SEQ. 
ID NO. 2 or to a SEQ. ID NO.: 4; and encodes one or more 
functional proteins having an amino acid sequence that is at 
least 95% similar to a SEQ. ID NO. 1 or to a SEQ. ID NO. 
US 8,772,454 B2 
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3. In one aspect the host cell is selected from one or more 
microbial cells, mammalian cells, Z-cells, E. coli cells, 
eukaryotic cells, plasmids prokaryotic cells, or any combina 
tions thereof. 
One embodiment of the present invention is directed 
towards a method of expressing a green fluorescent protein in 
a host cell comprising the steps of ligating one or more 
amplified nucleotides encoding the green fluorescent protein 
into a vector followed by inserting the vector into the host cell 
to express the green fluorescent protein. One aspect of the 
present invention describes a green fluorescent protein 
expressed by the method of the present invention. 
Another embodiment of the present invention is a method 
of isolating one or more expressed green fluorescent proteins 
comprising the steps of plating the one or more expressed 
green fluorescent proteins onto a culture plate, the culture 
plate is then incubated the culture at 37° C. for a period not 
less than 8 hours this is followed by selection and picking one 
or more green fluorescent colonies from the culture plate. The 
selected green fluorescent colonies are resuspended in water 
or a buffer; followed by plating onto a culture plate and 
incubation at room temperature for at least 48 hours. The 
green fluorescent colonies are resuspended in the buffer fol 
lowed by sonication in the buffer on ice. The sonicated buffer 
Solution is centrifuged and separated to yield a cleared lysate 
and a cellular debris. The expressed green fluorescent protein 
are isolated from the cleared lysate using metal-affinity chro 
matography, chromatography, affinity extraction, or other 
protein purification techniques. In one aspect the present 
invention described agreen fluorescent protein isolated by the 
method of the present invention. 
In a further embodiment the present invention describes a 
kit comprising one or more containers, wherein at least one of 
the containers comprises an isolated nucleic comprising a 
nucleotide sequence that is at least 95% homologous to a 
SEQ. ID NO. 2 or to a SEQ. ID NO. 4, an isolated protein 
molecule comprising an amino acid sequence, wherein the 
amino acid sequence is at least 95% identical to a SEQ. ID 
NO.: 1 or to a SEQ. ID NO. 3, or both. 
DESCRIPTION OF THE DRAWINGS 
For a more complete understanding of the features and 
advantages of the present invention, reference is now made to 
the detailed description of the invention along with the 
accompanying figures and in which: 
FIG. 1A depicts a phylogeny of the protein-coding 
sequences of all known copepod GFPs rooted with Chiridius 
poppei GFP (cpCFP), a copepod GFP from the related family 
Aetideidae. Scale bar: 0.05 substitutions per nucleotide site. 
The posterior probability at each node is 1.00 except where 
indicated; 
FIG. 1B shows the amino acid sequence alignment of 
selected copepod GFP proteins and Aquorea victoria GFP 
SEQ. ID NO.: 13. Chromophore-forming tripeptide is under 
lined. Both the tree and alignment were made using Geneious 
3.8 software (12-14). Organisms include C. poppei SEQ. ID 
NO.: 14 (cpGFP. Accession No. AB 185173), L. aestiva SEQ. 
ID NO.: 15 (laesGFP, No. AY268073), unidentified Pontella 
SEQ. ID NO.: 16 (pdae1GFP. AY268076), P. meadi SEQ. ID 
NO.: 17 and SEQ. ID NO.: 18 (pmeaGFP1 and GFP2, Nos. 
AY268.074 and AY268.075), and P plumata SEQ. ID NO.: 19 
and SEQ. ID NO. 20 (ppluCFP1 and GFP2, Nos. AY268071 
and AY268072), and Pontella mimocerami SEQ. ID NO.: 1 
and SEQ. ID NO. 3 (pmimGFP1 and GFP2): 
FIG. 2 shows Normalized excitation (dashed line) and 













pmimGFP2. Horizontal axis: wavelength in nanometers; ver 
tical axis: fluorescence amplitude. Dashed line represents 
excitation maximum at 491 nm, Solidline represents emission 
maximum at 505 nm for both pmimGFP isoforms; 
FIG. 3A shows recombinant fluorescent proteins electro 
phoresed on a SDS-containing gel without prior heating and 
viewed with UV illumination. p.mimGFP1 fluoresces 
brightly, pmimGFP2 is also visible, but is very faint. rGFP is 
a monomer, DSRed is a tetramer (indicated by an arrow); 
FIG. 3B is the same semi-denatured gel as in FIG. 3A, but 
imaged with Coomassie stain. rGFP. pmimGFP1, and 
pmimGFP2 are all susceptible to partial denaturation under 
the running conditions and therefore show non-fluorescent 
bands at ~25kD, the expected size of a fully denatured pro 
tein. Dsked, the tetrameric standard, retains its multimeric 
State; 
FIG. 3C shows the same samples as in FIGS. 3A and 3B. 
but electrophoresed in fully denaturing conditions (before 
loading, the samples were boiled 5 min) followed by Coo 
massie stain. All four samples show the single major band 
corresponding to the denatured protein at about 25 kD; 
FIG. 3D shows the removal of N-terminal positive charges 
reduces aggregation. Lane 1 is the wildtype pmimGFP1, lane 
2 K5E mutant, lane 3 is K5T mutant, and lane 4 is a triple 
mutant K5T, C8S, and R9A. Arrow indicates tetramer mobil 
ity; 
FIGS. 4A and 4B are photographic images showing Pon 
tella minocerami illuminated and imaged under white (4A) 
and blue light showing the bright green fluorescence (4B). 
Note the blue non-fluorescent coloration (FIG. 4A) is typical 
of many Pontellid species: 
FIGS.5A and 5B show pH (5A) and photo (5B) stability of 
novel copepod proteins and of the non-aggregating mutant of 
pmimGFP1. On both panels, analogous measurements of 
commercially available recombinant EGFP protein are pre 
sented as a reference. In FIG. 5B, the horizontal axis is time of 
illumination under the fluorescence microscope. In both fig 
ures, each point represents an average of three replicate mea 
Surements; 
FIG. 6A shows the amino acid sequence of pmimGFP1 
DS3 Pontella (SEQ. ID NO.: 1); 
FIG. 6B shows the nucleic acid sequence of pmimGFP1 
DS3 (SEQ. ID NO. 2); 
FIG. 7A shows the amino acid sequence of pmimGFP2 
DS3 Pontella (SEQ. ID NO. 3): 
FIG. 7B shows the nucleic acid sequence of pmimGFP2 
DS3 (SEQ. ID NO. 4): 
FIG. 8A shows the amino acid sequence of mutant 1: 
pmimGFP1 with K5E amino acid change (SEQ. ID NO. 5): 
FIG. 8B shows the nucleic acid sequence of mutant 1: 
pmimGFP1 with K5E amino acid change (SEQ. ID NO.: 6): 
FIG. 9A shows the amino acid sequence of mutant 3: 
pmimGFP1 with K5T, C8S, and R9A amino acid changes 
(SEQ. ID NO.: 7); and 
FIG. 9B shows the nucleic acid sequence of mutant 3: 
pmimGFP1 with K5T, C8S, and R9A amino acid changes 
(SEQ. ID NO. 8). 
DESCRIPTION OF THE INVENTION 
While the making and using of various embodiments of the 
present invention are discussed in detail below, it should be 
appreciated that the present invention provides many appli 
cable inventive concepts that can be embodied in a wide 
variety of specific contexts. The specific embodiments dis 
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cussed herein are merely illustrative of specific ways to make 
and use the invention and do not delimit the scope of the 
invention. 
To facilitate the understanding of this invention, a number 
of terms are defined below. Terms defined herein have mean 
ings as commonly understood by a person of ordinary skill in 
the areas relevant to the present invention. Terms such as “a”, 
“an and “the are not intended to refer to only a singular 
entity, but include the general class of which a specific 
example may be used for illustration. The terminology herein 
is used to describe specific embodiments of the invention, but 
their usage does not delimit the invention, except as outlined 
in the claims. 
As used herein, “nucleic acid' or “nucleic acid molecule' 
refers to polynucleotides. Such as deoxyribonucleic acid 
(DNA) or ribonucleic acid (RNA), oligonucleotides, frag 
ments generated by the polymerase chain reaction (PCR), and 
fragments generated by any of ligation, Scission, endonu 
clease action, and exonuclease action. Nucleic acid mol 
ecules can be composed of monomers that are naturally 
occurring nucleotides (such as DNA and RNA), or analogs of 
naturally-occurring nucleotides (e.g., C-enantiomeric forms 
of naturally-occurring nucleotides), or a combination of both. 
Modified nucleotides can have alterations in Sugar moieties 
and/or in pyrimidine or purine base moieties. Sugar modifi 
cations include, for example, replacement of one or more 
hydroxyl groups with halogens, alkyl groups, amines, and 
azido groups, or Sugars can be functionalized as ethers or 
esters. Moreover, the entire sugar moiety can be replaced with 
sterically and electronically similar structures, such as aza 
Sugars and carbocyclic Sugar analogs. Examples of modifica 
tions in a base moiety include alkylated purines and pyrim 
idines, acylated purines or pyrimidines, or other well-known 
heterocyclic substitutes. Nucleic acid monomers can be 
linked by phosphodiester bonds or analogs of Such linkages. 
Analogs of phosphodiester linkages include phosphorothio 
ate, phosphorodithioate, phosphoroselenoate, phosphorodis 
elenoate, phosphoroanilothioate, phosphoranilidate, phos 
phoramidate, and the like. The term “nucleic acid molecule' 
also includes so-called "peptide nucleic acids, which com 
prise naturally-occurring or modified nucleic acid bases 
attached to a polyamide backbone. Nucleic acids can be either 
single stranded or double Stranded. 
An "isolated nucleic acid molecule' as used herein is a 
nucleic acid molecule that is not integrated in the genomic 
DNA of an organism. For example, a DNA molecule that 
encodes a growth factor that has been separated from the 
genomic DNA of a cell is an isolated DNA molecule. Another 
example of an isolated nucleic acid molecule is a chemically 
synthesized nucleic acid molecule that is not integrated in the 
genome of an organism. A nucleic acid molecule that has been 
isolated from a particular species is Smaller than the complete 
DNA molecule of a chromosome from that species. 
As used herein the terms “protein’.“polypeptide' or “pep 
tide' refer to compounds comprising amino acids joined via 
peptide bonds and are used interchangeably. A "polypeptide' 
is a polymer of amino acid residues joined by peptide bonds, 
whether produced naturally or synthetically. Polypeptides of 
less than about 10amino acid residues are commonly referred 
to as "peptides. A "protein’ is a macromolecule comprising 
one or more polypeptide chains. A protein may also comprise 
non-peptidic components, such as carbohydrate groups. Car 
bohydrates and other non-peptidic substituents may be added 
to a protein by the cell in which the protein is produced, and 













terms of their amino acid backbone structures; substituents 
Such as carbohydrate groups are generally not specified, but 
may be present nonetheless. 
An "isolated polypeptide or protein’ is a polypeptide or 
protein that is essentially free from contaminating cellular 
components, such as carbohydrate, lipid, or other proteina 
ceous impurities associated with the polypeptide in nature. 
Typically, a preparation of isolated polypeptide contains the 
polypeptide in a highly purified form, i.e., at least about 80% 
pure, at least about 90% pure, at least about 95% pure, greater 
than 95% pure, or greater than 99% pure. One way to show 
that a particular protein preparation contains an isolated 
polypeptide is by the appearance of a single band following 
sodium dodecyl sulfate (SDS)-polyacrylamide gel electro 
phoresis of the protein preparation and Coomassie Brilliant 
Blue staining of the gel. However, the term "isolated does 
not exclude the presence of the same polypeptide in alterna 
tive physical forms, such as dimers or alternatively glycosy 
lated or derivatized forms. 
The term “homology” as used herein refers to the extent to 
which two nucleic acids are complementary. There may be 
partial or complete homology. A partially complementary 
sequence is one that at least partially inhibits a completely 
complementary sequence from hybridizing to a target nucleic 
acid and is referred to using the functional term “substantially 
homologous.” The degree or extent of hybridization may be 
examined using a hybridization or other assay (such as a 
competitive PCR assay) and is meant, as will be known to 
those of skill in the art, to include specific interaction even at 
low stringency 
As used herein the term “gene' is used to refer to a func 
tional protein, polypeptide or peptide-encoding unit. As will 
be understood by those in the art, this functional term includes 
both genomic sequences, cDNA sequences, or fragments or 
combinations thereof, as well as gene products, including 
those that may have been altered by the hand of man. Purified 
genes, nucleic acids, protein and the like are used to refer to 
these entities when identified and separated from at least one 
contaminating nucleic acid or protein with which it is ordi 
narily associated. 
As used herein, the term “vector” is used in reference to 
nucleic acid molecules that transfer DNA segment(s) from 
one cell to another. The vector may be further defined as one 
designed to propagate specific sequences, or as an expression 
vector that includes a promoter operatively linked to the spe 
cific sequence, or one designed to cause Such a promoter to be 
introduced. The vector may exist in a state independent of the 
host cell chromosome, or may be integrated into the host cell 
chromosome 
As used herein an “expression vector is a nucleic acid 
molecule encoding a gene that is expressed in a host cell. 
Typically, an expression vector comprises a transcription pro 
moter, a gene, and a transcription terminator. Gene expression 
is usually placed under the control of a promoter, and Such a 
gene is said to be “operably linked to the promoter. Simi 
larly, a regulatory element and a core promoter are operably 
linked if the regulatory element modulates the activity of the 
core promoter. 
As used herein the term "host cell refers to cells that have 
been engineered to contain nucleic acid segments or altered 
segments, whether archeal, prokaryotic, or eukaryotic. Thus, 
engineered, or recombinant cells, are distinguishable from 
naturally occurring cells that do not contain recombinantly 
introduced genes through the hand of man. 
The term “sequences” as used herein is used to refer to 
nucleotides or amino acids, whether natural or artificial, e.g., 
modified nucleic acids or amino acids. When describing 
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“transcribed nucleic acids' those sequence regions located 
adjacent to the coding region on both the 5', and 3' ends Such 
that the deoxyribonucleotide sequence corresponds to the 
length of the full-length mRNA for the protein as included. 
The term “gene' encompasses both cDNA and genomic 
forms of a gene. A gene may produce multiple RNA species 
that are generated by differential splicing of the primary RNA 
transcript. cDNAS that are splice variants of the same gene 
will contain regions of sequence identity or complete homol 
ogy (representing the presence of the same exon orportion of 
the same exon on both cDNAs) and regions of complete 
non-identity (for example, representing the presence of exon 
“A” on cDNA I wherein cDNA2 contains exon “B” instead). 
Because the two cDNAS contain regions of sequence identity 
they will both hybridize to a probe derived from the entire 
gene or portions of the gene containing sequences found on 
both cDNAs; the two splice variants are therefore substan 
tially homologous to such a probe and to each other 
The terms “a sequence essentially as set forth in SEQID 
NO. (ii)”, “a sequence similar to “a sequence identical to’, 
“nucleotide sequence' and similar terms, with respect to 
nucleotides, refers to sequences that Substantially correspond 
to any portion of the sequence identified herein as SEQ ID 
NOS.: 1-12. These terms refer to synthetic as well as natu 
rally-derived molecules and include sequences that possess 
biologically, immunologically, experimentally, or otherwise 
functionally equivalent activity. 
As used herein, the term “polymerase chain reaction' 
(PCR) refers to the method of K. B. Mullis U.S. Pat. Nos. 
4,683,195,4,683.202, and 4,965,188, hereby incorporated by 
reference, which describe a method for increasing the con 
centration of a segment of a target sequence in a mixture of 
genomic DNA without cloning or purification. This process 
for amplifying the target sequence consists of introducing a 
large excess of two oligonucleotide primers to the DNA mix 
ture containing the desired target sequence, followed by a 
precise sequence of thermal cycling in the presence of a DNA 
polymerase. The two primers are complementary to their 
respective strands of the double stranded target sequence. To 
effect amplification, the mixture is denatured and the primers 
then annealed to their complementary sequences within the 
target molecule. Following annealing, the primers are 
extended with a polymerase so as to form a new pair of 
complementary strands. The steps of denaturation, primer 
annealing and polymerase extension can be repeated many 
times (i.e., denaturation, annealing and extension constitute 
one “cycle'; there can be numerous “cycles') to obtain a high 
concentration of an amplified segment of the desired target 
sequence. The length of the amplified segment of the desired 
target sequence is determined by the relative positions of the 
primers with respect to each other, and therefore, this length 
is a controllable parameter. By virtue of the repeating aspect 
of the process, the method is referred to as the “polymerase 
chain reaction’ (hereinafter "PCR). Because the desired 
amplified segments of the target sequence become the pre 
dominant sequences (in terms of concentration) in the mix 
ture, they are said to be “PCR amplified”. With PCR, it is 
possible to amplify a single copy of a specific target sequence 
in genomic DNA to a level detectable by several different 
methodologies (e.g., hybridization with a labeled probe; 
incorporation of biotinylated primers followed by avidin 
enzyme conjugate detection; incorporation of P-labeled 
deoxynucleotide triphosphates, such as DCTP or DATP, into 
the amplified segment). In addition to genomic DNA, any 
oligonucleotide sequence can be amplified with the appropri 













ments created by the PCR process itself are, themselves, 
efficient templates for subsequent PCR amplifications. 
The present invention describes the isolation and charac 
terization of two protein isoforms collected green fluorescent 
copepods. The cDNA expression libraries synthesized from 
the isolated mRNA yielded the genes responsible for the 
green fluorescence in the Pontellid copepods and indicated 
similarities to the GFP first isolated from the jellyfish Aequo 
rea victoria. 
The two isolated Pontella minocerami GFP-like isoforms 
are 72% similar to the other known copepod GFP-like pro 
teins, but are much more similar to other Pontellid GFP-like 
proteins than to the distantly related fluorescent copepod 
Chiridius poppei (family Aetideidae). The new isoforms are 
quick to mature, rapidly producing a fluorescent signal. The 
two isoforms are very similar in molar extinction coefficients 
(ME) with 105,000 M'cm for pmimGFP1 and 103,000 
Mcm for pmimGFP2. Quantum yields of pmimGFP1 and 
pmimGFP2 are 0.94 and 0.92, respectively. The relative 
brightness of these two new copepod GFP-like proteins is the 
highest measured for any isolated GFP-like protein. 
Fluorescent proteins (FPs) have revolutionized biomedical 
research. Because of their ability to self-assemble and their 
non-invasive, non-cytotoxic qualities, fluorescent proteins 
have been adapted for myriad uses in the labCFP and its 
derivatives have accelerated life science research by being 
extensively used as genetically encoded in situ and in vivo 
markers' since first being isolated from the jellyfish 
Aequorea victoria, phylum Cnidaria" To date, about 120 
fluorescent and colored GFP-like proteins had been cloned 
only from hydrozoans and anthozoans of the phylum Cni 
daria. Past rationale suggested that fluorescent proteins would 
be exclusively found in cnidarians and that these proteins 
would also necessarily be coupled to the luminescent systems 
that are common in these marine animals." However, this 
dogma was rejected with the discovery that GFP-like proteins 
could be isolated from other non-luminescent organisms such 
as corals (Phylum Cnidaria, class Anthozoa), copepods (phy 
lum Arthropoda, class Crustacea), and amphioxus (phylum 
Chordata, subphylum Cephalochordata).'' 
So far only seven GFP-like proteins have been identified 
from the copepod families Pontellidae and Aetideidae.''' In 
general, the GFP-like proteins from this group of arthropods 
have qualities such as rapid maturation, high brightness, and 
increased photostability, all extremely valuable for use as a 
biotechnology tool. Isolation and characterization of more 
GFP-like proteins in Pontellidae will likely continue to pro 
vide a better source from which to harvest fluorescent pro 
teins that may be adapted for use in the laboratory and in 
biomedical research. 
In the present invention, the inventors cloned, and charac 
terized two novel genes coding for GFP-like proteins from a 
Pontellid copepod (Pontella mimocerami, first described by 
Fleminger, 1957)' in the Atlantic Ocean off the coast of the 
Bahamas Islands along with the isolation and characteriza 
tion of two novel GFP-like protein isoforms, pmimGFP1 and 
pmimGFP2. The two isoforms are similar in their amino acid 
sequences (FIGS. 6A and 7A, respectively) and share similar 
spectral characteristics to each other as well as to other cope 
pod GFP-like proteins. The nucleic acid sequences of 
pmimGFP1 and pmimGFP2, are shown in FIGS. 6B and 7B, 
respectively. However, the two isoforms of the present inven 
tion are the brightest isolated green fluorescent proteins to 
date. 
Pontella mimocerami collection and total RNA isolation: 
The copepods were collected during a Sunset plankton tow off 
the stern of the RV Seward Johnson during the 2007 Deep 
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Scope Cruise. The samples were collected at 25°1.3'N, 
77°36.2W by towing a 200 m plankton net at 5-15 ft below 
the surface at 1 knot for 20 minutes. After 20 minutes, the net 
was removed and the collected organisms were inspected 
with blue light illumination (BlueStar, NightSea; Andover 
Mass.) to excite the fluorescent proteins. The organisms were 
photographed under white and blue light provided by a Leica 
light source and filter (Canon Powershot G6, Leica MZFLIII 
microscope, and Chroma filter #11003 BL/VIO, FIG. 4). 
Several green fluorescent copepods were transferred to an 
empty culture dish with a transfer pipette and identified to the 
family level, Pontellidae. Total RNA was extracted using a 
commercial kit (Ambion's RNAqueous kit) according to 
manufacturer's protocol and the samples were stored on 
board the ship in 6.65 M LiCl at -80°C. The specimens for 
identification were preserved by freezing in Tissue-Tek 
O.C.T. compound and stored at -80° C. (Sakura Finetek; 
Torrance, Calif.). 
Preparation and screening of bacterial clNA expression 
library: cloNA was synthesized and PCR-amplified using 
SMART cDNA amplification kit (Clontech: Mountain View, 
Calif.) and SuperScript II reverse transcriptase (Invitrogen; 
Carlsbad, Calif.), with two modifications. First, a different 
oligonucleotide was used for priming the reverse transcrip 
tion reaction: 5'AAGCAGTGGTATCA ACGCAGAGTCG 
CAGTCGGTAC(T)V (where V stands for a mixture of A, 
G, and C bases) (SEQID NO.:9). For the first step in cDNA 
amplification, the following long oligonucleotide was used in 
lieu of the one provided with the SMART cDNA amplifica 
tion kit: AGT GGA CTATCC ATGAAC GCA AAG CAG 
TGGTATCAA CGC AGA GT3' (SEQID NO.10). The PCR 
reactions contained 0.3 uM of primers. The thermocycler 
profile was: 94° C. for 5 m, 94° C. for 40s, 68°C. for 4 m, 
cycle to step two for 26 additional cycles, hold at room tem 
perature. The product from this step was diluted 1:10 and 3 ul 
of this dilution was used for the second step in cDNA ampli 
fication. For this second amplification step, three separate 
reactions were performed. The first one used the same oligo 
nucleotide as in the first amplification step; the other two 
reactions used the same oligonucleotide, but extended by 
either one or two T bases at the 5' terminus. These PCR 
reactions contained 0.1 uM of primer, the thermocycler pro 
file was 94° C. for 5 m, 94° C. for 40s, 68° C. for 4 m, cycle 
to step two for 5 additional cycles, hold at room temperature. 
Such conditions bias the PCR amplification towards longer 
products', generating a cDNA sample enriched with full 
coding regions. Also, these additional amplifications ensured 
that upon ligation into vector, each cDNA species would be 
represented by inserts fused to the leading lacz peptide in all 
three possible reading frames. The products of amplification 
were purified using QIAquick PCR Purification Kit (Qiagen; 
Valencia, Calif.) and ligated into pGEM-T vector (Promega; 
Madison, Wis.) following manufacturers’ protocols. The 
ligations were transformed into TOP 10 chemically compe 
tent Escherichia coli cells (Stratagene; Cedar Creek, Tex.) 
and the total transformation expression library was plated 
onto Luria Burtani (LB)/Agar plates supplemented with 100 
ug/ml amplicillin and 1 mM Isopropyl B-D-1-thiogalactopy 
ranoside (IPTG). The plates were incubated overnight at 37° 
C. and then screened at one day post-transformation for green 
fluorescent colonies using a Leica MZFLIII microscope with 
GFP specific filter #51004v2 F/R (Chroma Technology 
Corp). A total of about 10 bacterial colonies were surveyed. 
Identification, expression, and purification of Pontella 
mimocerami GFP isoforms: GFP1 (SEQ ID NOS.: 1 and 2, 
amino acid and nucleic acid respectively) and GFP2 (SEQID 













From the expression plates, six green fluorescent colonies 
were identified and, were further picked into individual 3 ml 
LB/Amp (100 ug/ml final concentration) bacterial cultures 
and shaken overnight at 37°C. The cultures were processed 
using Qiagen's Spin Mini-Prep kit (Qiagen) following the 
manufacturer's protocol. 500 ng of each of the six plasmids 
were sequenced using an ABI 3730 sequencer (Applied Bio 
systems). The sequences were aligned using SeqMan2 soft 
ware (DNASTAR Lasergene 7.2) and gene identity was con 
firmed by BLASTX searching non-redundant protein 
databases. The amino acid sequences were used to construct 
a phylogenetic tree using neighbor joining and displaying 
Substitutions per site as well as an alignment of the pmimG 
FPs and other copepod proteins with Genious software." 
From the amino acid sequences two GFP-like isoforms 
were identified (SEQID NOS.: 1 and 3). Two plasmid con 
structs, pmimGFP1 and pmimGFP2, were chosen represent 
ing both isoforms to use as templates to re-amplify the gene 
coding regions with an N-terminus Shine-Dalgarno 
sequence, 5'TTGATTGATTGAAGGAGAAAT ATCATG 
(SEQ ID NO.:11) and a C-terminus 6-histidine tag, 5' CAT 
CAC CAT CAC CAT CAC TAAA (SEQ ID NO.12).''' 
The primers were designed to be in frame with the gene 
specific primer for each isoform. The resulting amplicons 
were ligated into the same pGEM-T vector from Promega, but 
then transformed into protein expression specific Z cells 
(Zymo Research, Orange, Calif.). The transformations were 
plated onto LB/Agar plates Supplemented with 1XAmp and 
1xIPTG (concentrations as previously noted), and incubated 
overnight at 37°C. One green fluorescent colony was picked 
from each plate, resuspended in 20LL of water, and streaked 
onto fresh LB/Agar plates supplemented with 1xAmp and 
1xIPTG (concentrations as previously noted), and incubated 
overnight at 37°C. One green fluorescent colony was picked 
from each plate, Suspended in 20 uL of water, and streaked 
onto fresh LB/Agar plates supplemented with 100 ug/ml 
ampicillin and 1 mM IPTG. After a two-day incubation at 
room temperature, the colonies were harvested from plates 
and Suspended in 1xEBS, Sonicated on ice, and centrifuged to 
remove the cellular debris. The inventors used the cleared 
lysate to isolate a purified solution of the green fluorescent 
protein using metal-affinity chromatography as implemented 
in QIAexpressionist system following the manufacturers 
protocol (Qiagen). The fluorescent proteins were eluted in 
500 mMimidazole in 1xRBS. The imidazole was removed by 
buffer exchange for 1xRBS by repeated centrifugation steps 
in a protein concentrator (Amicon Ultra-15, Millipore; Bil 
lerica, Mass.). 
Phylogenetic analysis: A nucleotide alignment of all cope 
pod GFP-like proteins was prepared with Geneious software 
v 3.7.' The Bayesian phylogenetic analysis was performed 
on the basis of coding nucleotide sequence alignment, using 
MrBayes software embedded within Geneious package.''' 
The Bayesian analysis was performed using a generalized 
time reversible model of the alignment was done to reveal the 
phylogenetic tree, rooted to the closely related Chiridius 
poppei''' An amino acid sequence alignment, including A. 
victoria GFP was prepared with Geneious software, v 3.8.' 
The trees were sampled every 200 steps generating 5,500 
trees, of which the first 5,000 were discarded (“burned'), and 
the remaining 500 trees were used to infer posterior probabili 
ties. The tree was rooted by the closely related cpGFP from 
Chiridius poppei, which comes from another family of cal 
anoid copepods (Aeteidae, 13). An amino acid sequence 
alignment, including A. victoria GFP, was prepared with 
Geneious software.' The analyzed sequences included GFPs 
from Chiridius poppei (cpCFP. Accession No. AB 185173), 
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Labidocera aestiva (laesGFP, No. AY268073), unidentified 
Pontella (pdae1GFP. AY268076), Pontella meadi 
(pmeaGFP1 and GFP2, Nos. AY268074 and AY268.075), and 
Pontella plumata (ppluGFP1 and GFP2, Nos. AY268071 and 
AY268072). 5 
Molar extinction measurements: Determination of the 
molar extinction coefficient (ME) was based on the fact that 
the green-emitting GFP chromophore in the alkali-denatured 
protein has a characteristic peak of absorption at 445 nm with 
a molar extinction coefficient of 44,000 liter mol'cm', 
which is independent of the sequence of the protein since the 
influence of the sequence-specific chromophore environment 
is removed by denaturation. This fact provides a useful inter 
nal standard for determination of the ME in the native state in 
any GFP-like protein with a GFP-like chromophore. This 
strategy was first suggested by Gurskaya et al, and since 
then was adopted in several studies characterizing natural 
GFP-like proteins. The measurement involves determin 
ing the absorption of the same concentration of the protein in 
alkali-denatured and native conditions, and calculating the 
native ME based on a simple proportion. Strictly speaking, 
the ME determined in this way correspond to the fully-formed 
GFP chromophore, not the protein; but since each properly 
functioning GFP-like polypeptide generates and hosts 
exactly one chromophore molecule, it is possible view this 
measurement as absorption of 1M concentration of protein 
chains under ideal conditions (100% chromophore biosyn 
thesis efficiency and no degradation). This measure is inde 
pendent of the oligomeric state of the protein, and is free of 
potential sources of error related to measurements of protein 
concentration or biases due to incomplete chromophore 
maturation, therefore providing grounds for comparison of 
brightness characteristics across GFP-like proteins from vari 
ous sources. In this study, to achieve better accuracy, the 
inventors measured the ME using a range of concentrations. 
Fluorescent proteins (0.8 ug. 2 Lig. 4 Lig, 6 Jug, and 8 Jug 
protein) were diluted in either denaturing (0.1M NaOH) or 
non-denaturing (1xPBS) buffers, in a total volume of 150 ul. 
The absorbance was read for all the samples from 400mm-550 
nm with a 5 nm interval. Then, the maximal absorbance 
values of the native proteins were plotted against the absor 
bances at 445 nm of the denatured proteins for the range of 
dilutions. The ME of the native protein was calculated as the 
slope of the linear regression of this graph multiplied by the 
ME of the denatured GFP chromophore at 445 nm (44,000 
liter mol'cm.). 
Fluorescence quantum yield measurements: To determine 
the quantum yield of fluorescence (QY, the fraction of pho 
tons emitted of the total number of photons absorbed), the 
same dilutions of the native proteins were excited at 450 nm 
and the relative fluorescence output between 480 nm and 600 
nm was determined by Summing up all the fluorescence val 
ues for each wavelength with a 5 nm interval. The same set of 
dilutions for the QY standards (fluorescein, QY=0.9 and 
EGFP. QY=0.6) were prepared and measured in a similar 
fashion. The total fluorescence for each dilution was plotted 
against the absorbance of each dilution at excitation wave 
length (450 nm). The QYs of the new proteins of the present 
invention were calculated by comparing the linear regression 
slopes of our samples to those of our standards. The error of 60 
the QYS measurements was calculated using the Delta 
method. For all quantitative spectroscopic measurements, 
SpectraMax M2 microplate reader with the provided soft 
ware (Molecular Devices, SoftMax Pro V5: Sunnyvale, 
Calif.) was used. 
Oligomerization and aggregation: To determine the oligo 












instant invention, the inventors analyzed the proteins using 
SDS-PAGE in a 4-15% gradient gel with SDS-Tris-Glycine 
buffers (Bio-Rad, Hercules, Calif.). To resolve GFP-like pro 
teins in the native state, the samples were not boiled before 
loading on the gel, and visualized after the run by their native 
fluorescence. This method of oligomerization assessment uti 
lizes the fact that most GFP-like proteins do not lose their 
oligomeric state or fluorescence unless boiled in SDS, and 
their mobility on an SDS gel roughly corresponds to their 
globular size. This was first noticed and exploited in studies of 
oligomerization of the red fluorescent protein DsRed', fol 
lowed by demonstration of the utility of this approach for 
assessing oligomerization in a variety of other GFP-like pro 
teins' . Since it is theoretically possible that SDS would 
disrupt oligomers but not unfold the protein, the method is 
applied conservatively, Such that the only result that is con 
sidered relevant is the presence of oligomerization or aggre 
gation, whereas the apparent lack of oligomerization does not 
necessarily imply the monomeric state of the protein in the 
absence of SDS. Since the mobility of such non-denatured 
protein does not correspond to its molecular weight measured 
by the markers that assume full polypeptide unfolding, a 
special set of standards for appropriate globule sizes is nec 
essary to evaluate the oligomeric state. In the present inven 
tion, as monomeric and tetrameric standards, the inventors 
used recombinant GFP (rGFP) and Dsked2 proteins, respec 
tively (Clontech, Mountain View, Calif.). In gels obtained in 
the present invention, the native monomeric GFP ran as a 
band at 37 kDa, while tetrameric Dshed2 ran at 60 kDa. The 
mobility of these standards was consistent across gels, mak 
ing it possible to use the standard marker lane (BioRad, 
Hercules, Calif.) to infer their position. In addition to SDS 
PAGE of unboiled samples with band visualization via native 
fluorescence, the inventors also ran the same samples after 
boiling (i.e., under fully denaturing conditions) on the same 
gels, and used coomassie staining to identify the bands spe 
cific for the unboiled samples. 
Site-directed mutagenesis: To reduce aggregation, the 
present invention describes several amino acid changes in the 
N-terminal that were introduced into the gene sequence using 
PCR with primers designed to amplify the gene. Mutant 1 
introduced K5E (SEQ ID NOS.:5 and 6, amino acid and 
nucleic acid respectively) as shown in FIGS. 8A and 8B, 
respectively, mutant 2 introduced K5T, and mutant 3 intro 
duced K5T, C8S, and R9A changes (SEQID NOS.: 7 and 8, 
amino acid and nucleic acid respectively, as seen in FIGS. 9A 
and 9B). Additionally, several internal amino acids were 
changed (139, 192, 221) were changed using Stratagene’s 
Site Directed Mutagenesis Kit. The modifications include 
mutating the Cys at 139 to Ser and the Phe at 192 and 221 to 
either Ala or Asp. These three amino acids (Cys and two Phe) 
were chosen specifically to change the oligomeric status of 
the native protein from a tetramer to an oligomer. 
pH stability: Chromophore sensitivities to changes in pH 
were assayed for pmimGFP1 pmimGFP2, pmimGFP1 (K5T, 
C8S, R9A), and EGFP (BioVision, Mountain View, Calif.). 
Roughly 10g of the proteins (5ug for eGFP) were incubated 
in buffers of varying pH for 10 min at 25°C., followed by 
measuring the maximum fluorescence intensity of each. All 
the proteins were excited at 450 nm and emission was mea 
sured from 480 to 600 nm. The buffers included: 0.1M gly 
cine/HCl (pHs 3.0 and 3.5), 0.1M sodium acetate (pHs 4.0, 
4.5, and 5.0), 0.1M phosphate (pH 6.0), 0.1M HEPES (pH 
7.0), 0.1M Tris/HCl (pHs 8.0 and 9.0), 0.1M carbonate (pHs 
10.0 and 11.0), 0.1Mphosphate/NaOH (pHs 11.5, 12.0, 12.5, 
and 13.0) and 0.1MNaOH (pH 13.5). Data were collected and 
graphed using the same instruments as for QY. 
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Photostability: 1 ul of protein solutions—EGFP (BioVi 
sion, Mountain View, Calif.), pmimGFP1, and pmimGFP1 
(K5T, C8S, R9A)—of approximately 1 lug/ml concentration 
were added to 100 ul of immersion oil (Fluka/Sigma, St. 
Louis, Mo.), were both vortexed for 5s to obtain emulsion. To 
generate negative control droplets, 1 ul of 1xPBS was emul 
sified in the same way and mixed in equal proportions with 
the protein emulsions. A droplet of this combined emulsion 
was placed onto a slide and slip-covered, with 3 replicate 
slides made for each protein. Individual droplets on the slides 
were illuminated through a 40x objective (Eclipse E600 
microscope, Super High Pressure Mercury Lamp, CFI PLAN 
APO 40x objective, FITC-HYQ filter, Nikon, Japan) over the 
course of 10 minutes while collecting images every 30s 
(exposure 800 ms, TV Lens C-0.6x, Nikon, OpenLab Soft 
ware by Improvision, UK). The integrated density (sum of all 
pixel values) of a non-fluorescent droplet (filled with 1xPBS) 
was used as a background and subtracted from the density of 
a corresponding fluorescent droplet (on the same slide), with 
the help of Image J software (National Institutes of Health, 
Bethesda, Md.). These values were plotted against time, and 
half-time of bleaching for the newly cloned proteins was 
inferred relative to EGFP. 
Sequence and phylogenetic analysis: The nucleotide-based 
phylogenetic tree of the new pmimGFPs in relation to all 
other copepod fluorescent proteins (FIG. 1A) show support at 
1.00 at every node except for where noted (posterior prob 
ability of 0.98 between pdae1GFP and the laesGFP/pmea/ 
pmim group). The amino acid sequences (SEQ ID NOS.:1 
and 3) of the two isoforms of our copepod GFPs are 97% 
similar to each other (only 6 amino acids difference) and are 
presented in alignment to other known copepod GFPs (FIG. 
1B). Overall, 37% of the amino acid sequence is identical 
among all of the copepod GFL-like sequences, and 72% of 
the sequence was conserved among all of the copepod GFP 
like sequences. The sequences are presented as a phyloge 
netic tree in relation to all other major groups of fluorescent 
proteins that have been characterized to date (FIG. 1A).'The 
amino acid sequences of the two isoforms of our copepod 
GFPs are 97% similar to each other (only 6 amino acids 
difference), and are presented in alignment to other known 
copepod GFPs using Geneious software (FIG. 1B)." 
Molar extinction coefficients and quantum yields of 
pmimGFP1 and pmimGFP2: Both of the purified Pontella 
GFPs were soluble in PBS with 500 mMimidazole during the 
final elution step of purification. However, when the imida 
Zole was removed, the proteins formed large aggregates that 
almost completely precipitated out of Solution. In order to 
perform the spectral and protein gel analyses, 250 mMimi 
dazole was added back to the protein solution, which re 
solubilized the aggregates. The spectral analyses revealed 
that the new copepod GFP-like proteins of the present inven 
tion are similar in some aspects to the other Pontellid GFP 
like proteins, with the exception of Chiridius poppei, a cope 
pod from the Aetideiae family. The molar extinction 
coefficients for pmimGFP1 and pmimGFP2 are 105,000 
Mcm and 103,000 M'cm respectively, notably higher 
than the average copepod molar extinction coefficient of 
about 89,000 M'cm'. Quantum yields of pmimGFP1 and 
pmimGFP2 are 0.94 and 0.92, respectively, notably exceed 
ing even the highest QY seen in a copepod species (Pontella 
meadi at 0.74). However, the calculated absorption and emis 
sion peaks of pmimGFP1 and pmimGFP2 (491 and 505 
respectively, FIG. 2) are very similar to the other copepod 
GFP-like proteins (absorbance max between 480-490 nm, 













SDS-PAGE of unboiled samples of the pmimGFP1 and 
pmimGFP2 shows native fluorescence as lower mobility 
bands as compared to the monomeric recombinant GFP 
(rGFP) and even tetrameric Dshed proteins (FIGS. 3A-3C), 
which Suggests aggregated of high-order oligomeric forms. 
There seems to be pronounced difference between 
pmimGFP1 and pmimGFP2 resistance to SDS-induced 
unfolding. In SDS-PAGE of unboiled samples, pmimGFP1 
fluoresces strongly, while pmimGFP2 is barely visible 
roughly at the tetramer mobility (FIG. 3A). Coomassie stain 
ing of the same lanes (FIG.3B) indicated that the majority of 
pmimGFP2 protein appears as a band at 25kDa, correspond 
ing to the mobility of the protein under fully denatured con 
ditions (note that every GFP-like protein in this gel actually 
unfolds somewhat in SDS even without boiling). FIG. 3C 
shows all of the proteins in a fully denatured state, with all 
protein masses around 25kDa. Both copepod proteins are 222 
amino acids long with a predicted molecular weight of 25 
kDa. 
A previous study demonstrated that, in many GFP-like 
proteins, the aggregation tendency can be reduced by replac 
ing a few positively charged amino acids in the N-terminus by 
neutral or negatively charged ones'. The present inventors 
chose to replace three amino acids, two positively charged 
ones (K5 and R9), and one cysteine (C8) as a potential disul 
phide bridge-forming one. FIG. 3D shows an SDS-PAGE of 
unboiled samples of mutants of pmimGFP1. Mutant 1 (K5E) 
shows increased mobility (i.e., less aggregation/oligomeriza 
tion), but also substantially decreased brightness. Mutant 2 
(K5T) is still very bright, but shows no change in mobility. 
Mutant 3 (K5T, C8S, R9A) matches the mobility of the tet 
rameric standard (DsRed2) and appears bright in the gel. 
From the above findings, it can be concluded that, although 
the mutagenesis alleviates aggregation, the best mutant pro 
tein of the present invention still forms oligomers, most likely 
tetramers. Despite its apparent brightness, the triple mutant 
also demonstrates diminished molar extinction coefficient 
(75,000M'cm) and quantum yield (0.35) incomparison to 
the parent protein, indicating that either the breakdown of the 
higher-order aggregates, or the effect of the particular muta 
tions within a single monomer, were detrimental for the pro 
tein's brightness characteristics. 
The new proteins are more stable in acidic pH than EGFP. 
demonstrating a pKa around 5.3-5.4, with the non-aggregat 
ing mutant of pmimGFP1 (K5T, CBS, R9A) being the most 
stable across the whole pH range, with the pKa of 4.7 (FIG. 
5A) pmimGFP2 also exhibits a tendency to be less bright in 
the neutral pH range, which, however, is not always repro 
ducible and may depend on other factors such as protein 
concentration and temperature fluctuations. The photostabil 
ity was assayed for the pmimGFP1 and its non-aggregating 
mutant relative to EGFP in the conditions approximating a 
typical application of the protein as a genetically encoded 
fluorescent label, by comparing the rates of photobleaching of 
protein emulsion droplets under the fluorescent microscope 
(FIG.5B). The time to half-photobleaching of pmimGFP1 is 
0.8 of EGFP, while its non-aggregating mutant is essentially 
identical to EGFP in this regard. Both pmimGFP1 and its 
mutant show non-exponential dynamics of photobleaching, 
with the highest photobleaching rate at the start of exposure. 
Notably, past the half-bleaching point both proteins pho 
tobleach at a similar rate, which is slightly lower than for 
EGFP (FIG. 5B). 
Copepod luminescence was first documented long ago, but 
it was also observed that some luminescent species exhibited 
an additional fluorescence located at the site of the luminous 
glands.' ' However, the genus of copepods that were col 
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lected in the present invention, Pontella, exhibited only green 
fluorescence and no luminescence. Since these organisms 
are not luminescent, it eliminated the need for the fluorescent 
protein serving as a chromatic shift agent, hinting that green 
fluorescence in these creatures can serve Some other function. 
Although copepods don’t feature compound eyes such as 
Some other crustaceans, the Pontellidae nauplius eye is well 
developed, featuring an elaborate triple-lens construction in 
the enlarged ventral eyes in the males’ and even though the 
biological roles for Pontellidae fluorescence are not proven, 
having well developed eyes in males may assist in locating 
brightly fluorescent females and interspecies signaling. Pon 
tellidae fluorescence may also offer protective counter-shad 
ing, i.e., protecting the copepods from recognition in their 
oceanic environment this function would be analogous 
to the well-documented function of bioluminescence in dim 
ocean zones.’’’7 
Sequence analysis revealed that pmimGFP1 and 
pmimGFP2 proteins had their N-terminal methionines intact, 
which was not the case with the Chiridius poppei GFP-like 
protein.'" Masuda Suggested that this may be due to post 
translational excision of the methionine by bacterial methio 
nyl-aminopeptidase (MAP). The second amino acid in the C. 
poppei GFP-like protein is threonine, which is known to leave 
the primary methionine Vulnerable to removal. All of the 
Pontellid GFP-like proteins have a proline in the second posi 
tion, which may be protective. These similarities contrib 
ute Support for the closer phylogenetic relationships among 
the Pontellid GFP-like proteins. FIG. 1A represents the phy 
logenetic tree of all of the known copepod GFP-like proteins. 
The tree Suggests that C. poppei is at least closely related to 
the other Pontellid copepod species, expected since C. poppei 
belongs to a different copepod family, Aetideidae. The light 
transforming chromophores of both pmimGFP1 and 
pmimGFP2 proteins contain the same amino acid sequence, 
Gly-Tyr-Gly, as the other known copepod GFP-like proteins: 
the Tyr and second Gly are strictly conserved among all 
fluorescent proteins. Also, the Arg and Glu amino acids 
responsible for the autocatalytic steps of chromophore for 
mation are present at positions 96 and 222, respectively GFP 
numbering (positions 87 and 221 in the pmimGFPs). Cope 
pod GFP-like sequences tend to lack tryptophan residues: 
pmimGFP1 and pmimGFP2 each have only one at position 
158. The only other copepod GFP-like protein to contain 
tryptophan is from L. aestiva, which may share a common 
ancestor with the two new copepod fluorescent isoforms. 
The molar extinction and quantum yield data reveal that the 
new Pontella GFP-like proteins of the present invention are 
the brightest green fluorescent proteins to be isolated in their 
native forms with a relative brightness of 120M'cm (prod 
uct of the molar extinction coefficient and the quantum yield). 
Only one other fluorescent protein, a derived form of dsRed 
called tdTomato approaches the brightness of the pmimGFPs 
with a relative brightness of 95 Mcm'.” Both pmimGFP1 
and pmimGFP2 isoforms are almost three times brighter than 
the P plumata GFP-like proteins, more than 1.5 times 
brighter than all of the other copepod GFP-like proteins, and 
more than five times brighter than the cardinal GFP from A. 
victoria. Thus, these new pmim copepod GFP-like proteins 
make excellent reporter proteins.” 
Although the first GFP-like proteins from copepods were 
Suggested to be monomeric, it has since been established that 
some were tetramers. The data from the present invention 
Suggests that pmimGFP1 exists in a multimeric form of at 
least a tetramer (FIGS. 3A to 3C), not unusual for fluorescent 
proteins PmimGFP2, despite very high sequence similarity to 













of SDS: it almost completely unfolds even when the sample is 
not heated, with the remaining native protein running as a 
very faint band roughly corresponding to the tetrameric size 
(FIGS. 3A-3C). The only protein in the gel that is monomeric 
is rCFP; dsRED, a red fluorescent protein, is a tetramer. 
Both pmimGFP1 and pmimGFP2 aggregate and almost 
completely precipitate out of solution. Evdokimov noted a 
similar tendency to aggregate in the copepod GFP-like pro 
tein, ppluGFP2, and suggested this aggregation may be the 
result of electrostatic interactions between the charged sur 
faces of the fluorescent protein.'" Evdokimov's research 
used a site-directed mutagenesis approach to develop a non 
aggregating version of ppluGFP2 protein, now designated as 
TurboGFP. In the present invention several amino acid resi 
dues (K5, C8, and R9) at the N-terminus were replaced with 
others (E. T. S. or A) that are less likely to enhance aggrega 
tion' as well as to remove the 6xHis tag. Mutant 3 of the 
present invention, containing all three amino acid changes 
and the removed his tag, was the most Successful mutant since 
it does not show aggregation beyond the tetrameric level and 
appears bright on the gel, although its quantum yield (0.35) 
becomes Substantially less than in the parental protein. 
The brightness of a GFP-like protein is proportional to the 
product of two factors: molar extinction coefficient (ME) and 
quantum yield (QY). Of these, ME strongly depends on the 
excitation wavelength, in the fashion described by the absorp 
tion spectrum of the protein. With a particular application in 
mind, it may be useful to compare the brightness character 
istics of all proteins at a fixed excitation wavelength dictated 
by the application, which is sometimes done by companies 
advertising their GFP-related markers. In most cases, how 
ever, to compare general photophysical properties of GFP 
like proteins their brightness is defined as a product of QY and 
ME at the own absorption maximum of each protein, for 
which the standard reported ME corresponds. This “calcu 
lated brightness” is different from the absolute brightness, 
which is defined as the number of photons emitted divided by 
the number of photons incident on the chromophore, but is 
assumed to be directly proportional to it and hence represents 
a useful measure for comparison. In terms of calculated 
brightness, the new Pontella mimocerami proteins described 
herein are the brightest green emitting fluorescent proteins 
known to date, with a calculated brightness of 95,000-99,000 
M'cm'. Only one other fluorescent protein, a red protein 
derived from DsRed called tdTomato, approaches this value 
with a calculated brightness of 95,000 M'cm (35). The 
calculated brightness of the new proteins is three-fold greater 
than the one of EGFP, the most widely used genetically 
encoded fluorescent marker. Thus, these new copepod GFP 
like proteins have a good potential to become excellent 
reporters, at least in applications that tolerate oligomeric FP 
labels (such as monitoring promoteractivity, organelle track 
ing, or cell and tissue labeling). Still, their very high aggre 
gation tendency would be a problem even for Such applica 
tions, which prompted the present inventors to create a mutant 
of pmimGFP1 that does not aggregate (although still oligo 
merizes). Interestingly, the non-aggregating mutant demon 
strates a higher pH stability (pKa=4.7) than its ancestral 
pmimGFP1, but has a calculated brightness of only 26,000 
M'cm. Additional random mutagenesis may help to 
restore some of the lost brightness. Further mutagenesis is 
also required for adaptation of the new proteins for imaging 
applications involving molecular fusions, which must rely on 
monomeric protein tags. 
The present invention describes two novel FPs from Pon 
tella minocerami (Copepoda, Calanoida, Pontellidae), col 
lected off the coast of the Bahamas Islands. These two pro 
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teins, pmimGFP1 and pmimGFP2, were identified via 
fluorescence screening bacterial clNA expression library 
prepared from whole-body RNA of P. mimocerami. The FPs 
described hereinabove, have high molar extinction coeffi 
cients (105,000 Mcm for pmimGFP1 and 103,000 
M'cm' for pmimGFP2), as well as high quantum yields 
(0.94 for pmimGFP1 and 0.92 for pmimGFP2). The spectro 
scopic characteristics of the two FPs from P. mimocerami 
make them the brightest green FPS ever described in the 
literature, whether isolated from a natural source or engi 
neered in the laboratory. Because of this, these proteins area 
valuable addition to any in vivo imaging toolkit. 
It is contemplated that any embodiment discussed in this 
specification can be implemented with respect to any method, 
kit, reagent, or composition of the invention, and vice versa. 
Furthermore, compositions of the invention can be used to 
achieve methods of the invention. 
It will be understood that particular embodiments 
described herein are shown by way of illustration and not as 
limitations of the invention. The principal features of this 
invention can be employed in various embodiments without 
departing from the scope of the invention. Those skilled in the 
art will recognize, or be able to ascertain using no more than 
routine experimentation, numerous equivalents to the specific 
procedures described herein. Such equivalents are considered 
to be within the scope of this invention and are covered by the 
claims. 
All publications and patent applications mentioned in the 
specification are indicative of the level of skill of those skilled 
in the art to which this invention pertains. All publications and 
patent applications are herein incorporated by reference to the 
same extent as if each individual publication or patent appli 
cation was specifically and individually indicated to be incor 
porated by reference. 
The use of the word “a” or “an' when used in conjunction 
with the term “comprising in the claims and/or the specifi 
cation may mean "one.” but it is also consistent with the 
meaning of “one or more.” “at least one.” and “one or more 
than one.” The use of the term 'or' in the claims is used to 
mean “and/or unless explicitly indicated to refer to alterna 
tives only or the alternatives are mutually exclusive, although 
the disclosure supports a definition that refers to only alter 
natives and “and/or.” Throughout this application, the term 
“about is used to indicate that a value includes the inherent 
variation of error for the device, the method being employed 
to determine the value, or the variation that exists among the 
study Subjects. 
As used in this specification and claim(s), the words "com 
prising (and any form of comprising. Such as “comprise' and 
“comprises”), “having (and any form of having, such as 
“have” and “has'), “including (and any form of including, 
such as “includes and “include’) or “containing (and any 
form of containing, such as “contains' and "contain’) are 
inclusive or open-ended and do not exclude additional, unre 
cited elements or method steps. 
The term “or combinations thereofas used herein refers to 
all permutations and combinations of the listed items preced 
ing the term. For example, A, B, C, or combinations thereof 
is intended to include at least one of A, B, C, AB, AC, BC, or 
ABC, and if order is important in a particular context, also 
BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing 
with this example, expressly included are combinations that 
contain repeats of one or more item or term, such as BB, 
AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and 
so forth. The skilled artisan will understand that typically 
there is no limit on the number of items or terms in any 













All of the compositions and/or methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described interms of preferred embodiments, it will be appar 
ent to those of skill in the art that variations may be applied to 
the compositions and/or methods and in the steps or in the 
sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
All Such similar Substitutes and modifications apparent to 
those skilled in the art are deemed to be within the spirit, 
Scope and concept of the invention as defined by the appended 
claims. 
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Met Pro Asn Met Lys Lieu. Glu. Cys Arg Ile Ser Gly Thr Met Asn Gly 
1. 5 1O 15 
Glu Glu Phe Glu Lieu Val Gly Asn Gly Asp Gly Asn. Thir Asp Glu Gly 
3 O 2O 25 






















































<210 SEQ ID NO 2 
&211s LENGTH: 666 
&212s. TYPE: DNA 
<213> ORGANISM: Pontella mimocerami 
<4 OOs, SEQUENCE: 2 
21 
4 O 
His Val Lieu. 
55 
Tyr Glu Asn 
70 
Thr Arg Thr 
Asn Tyr Arg 
Gly Thr Gly 
12 O 
Llys Ser Asn 
135 
Lieu Wall Asn 
150 
Tyr Ser Ala 
Pro Thir Met 
Glu Glu Lieu. 
2OO 
Val Phe Lys 
215 












< 4 OOs 
atggagatgg aaa.cactgat 
citct ct cott ct c toccitac 
ctacct tccc togctggatat 
Ctalacacaag aactgagagg 
gatatgaagg agacaagatc 
acagoatcat citt cactgac 
c caaggctga caatatt citt 
gatact actic tdct caggto 
tgcticcagaa tigtggat.cc 
Ctgaagttgg tattgttgag 
SEQ ID NO 3 
LENGTH: 222 
TYPE : 



















































































































Met Pro Asn Met Lys Lieu. Glu. Cys Arg Ile Ser Gly Thr Met Asin Gly 
1. 5 15 












Arg Met Thir Asn Llys Val Llys Ser 
35 4 O 
Pro Tyr Lieu. Leu Ser His Val Lieu. 
SO 55 
Thr Phe Pro Ala Gly Tyr Glu Asn 
65 70 
Gly Gly Tyr Ser Asn Thr Arg Thr 
85 
Ile Ser Ala Thr Phe Asn Tyr Arg 
Asp Phe Llys Val Val Gly Thr Gly 
115 12 O 
Thir Asp Llys Ile Ile Llys Ser Asn 
13 O 135 
Lys Ala Asp Asn. Ile Lieu Val Asn 
145 150 
Arg Asp Gly Gly Tyr Tyr Ser Ala 
1.65 
Lys Ser Ala Ile His Pro Thr Met 
18O 
Thir Tyr Arg Llys Val Glu Glu Lieu 
195 
Val Glu Tyr Gln His Val Phe Lys 
210 
<210s, SEQ ID NO 4 
&211s LENGTH: 666 
&212s. TYPE: DNA 
215 
25 
Thr Lys Gly 
Gly Tyr Gly 
Val Tyr Lieu. 
Glu Arg Tyr 
90 
Tyr Glu Gly 
105 
Phe Pro Thir 
Pro Thr Cys 
Ala Tyr Thr 
155 
Glin Wall Asn 
17O 
Lieu. Glin Asn 
185 
His Thr Glin 
Arg Pro Thr 
<213> ORGANISM: Pontella mimocerami 
<4 OOs, SEQUENCE: 4 
atgcc.caa.ca tdaagcttga 
Cttgttggtg Ctggagaagg 
acca agggac ct citcc cctt 
taccactato ctacct tcc.c 
ggaggittact C caacaccag 
ttcaactaca gatatgaagg 
titc.cccacca acagoat cat 
cacatatacc cca aggctga 




<210s, SEQ ID NO 5 
&211s LENGTH: 222 























<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
amino acid sequence 



























































































<4 OOs, SEQUENCE: 5 
































































SEQ ID NO 6 
LENGTH: 666 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
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- Continued 
<210s, SEQ ID NO 7 
&211s LENGTH: 222 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
amino acid sequence 
<4 OO > SEQUENCE: 7 
Met Pro Asn Met Thr Lieu. Glu Ser Ala Ile Ser Gly Thr Met Asin Gly 
1. 5 1O 15 
Glu Glu Phe Glu Lieu Val Gly Asn Gly Asp Gly Asn. Thir Asp Glu Gly 
2O 25 3O 
Arg Met Thr Asn Lys Met Lys Ser Thr Lys Gly Pro Leu Ser Phe Ser 
35 4 O 45 
Pro Tyr Lieu. Leu Ser His Val Lieu. Gly Tyr Gly Tyr Tyr His Tyr Ala 
SO 55 6 O 
Thr Phe Pro Ala Gly Tyr Glu Asn Val Tyr Lieu. His Ala Met Lys Asn 
65 70 7s 8O 
Gly Gly Tyr Ser Asn. Thir Arg Thr Glu Arg Tyr Glu Asp Gly Gly Ile 
85 90 95 
Ile Ser Ala Thr Phe Asn Tyr Arg Tyr Glu Gly Asp Llys Ile Ile Gly 
1OO 105 11 O 
Asp Phe Llys Val Val Gly Thr Gly Phe Pro Thr Asn Ser Ile Ile Phe 
115 12 O 125 
Thr Asp Lys Ile Ile Llys Ser Asn Pro Thr Cys Glu. His Ile Tyr Pro 
13 O 135 14 O 
Lys Ala Asp Asn. Ile Lieu Val Asn Ala Tyr Thr Arg Thir Trp Met Lieu. 
145 150 155 160 
Arg Asp Gly Gly Tyr Tyr Ser Ala Glin Val Asn Asn His Met His Phe 
1.65 17O 17s 
Lys Ser Ala Ile His Pro Thr Met Leu Glin Asn Gly Gly Ser Met Phe 
18O 185 19 O 
Thr Tyr Arg Llys Val Glu Glu Lieu. His Thr Glin Thr Glu Val Gly Ile 
195 2OO 2O5 
Val Glu Tyr Gln His Val Phe Llys Thr Pro Thr Ala Phe Ala 
21 O 215 22O 
<210s, SEQ ID NO 8 
&211s LENGTH: 666 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic 
oligonucleotide 
<4 OOs, SEQUENCE: 8 
atgcc.caa.ca tacgcttga gtc.cgc.catc. tcc.ggalacca taacggaga ggagtttgaa 6 O 
Cttgttggta atggagatgg aaa cactgat gagggacgca taccaacaa gatgaagttcC 12 O 
acca agggac ct citct cott citctic cctac ttgct ct coc atgttcttgg c tatggatac 18O 
taccactato ctacct tccc togctggatat gaaaatgtct acctic catgc catgaagaat 24 O 
ggaggittact cta acacaag aactgagagg tatgaggatg gaggitat cat ttctgct acc 3OO 
ttcaactaca gatatgaagg agacaagatc attggggact tca aggttgt tdgaactgga 360 
titcc ctacca acagoatcat citt cactgac aaaataatca agt ccaa.ccc tacctgtgag 42O 
cacatc.tacc cca aggctga caat attctt gtgaatgcct acaccagaac ctdgatgctt 48O 
28 
agagatggtg gat act actic td 
catc.ccacca togcticcagaa td 
cacacacaaa citgaagttgg ta 
tttgct 
<210s, SEQ ID NO 9 
&211s LENGTH: 37 
&212s. TYPE: DNA 
<213> ORGANISM: Artifici 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
oligonucleotide 
<4 OOs, SEQUENCE: 9 
alagcagtggt at Caacgcag ag 
<210s, SEQ ID NO 10 
&211s LENGTH: 44 
&212s. TYPE: DNA 
<213> ORGANISM: Artifici 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
oligonucleotide 
<4 OOs, SEQUENCE: 10 
agtggact at C catgaacgc aa 
<210 SEQ ID NO 11 
&211s LENGTH: 27 
&212s. TYPE: DNA 
<213> ORGANISM: Artifici 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
oligonucleotide 
<4 OOs, SEQUENCE: 11 
ttgattgatt gaaggaga aa ta 
<210s, SEQ ID NO 12 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artifici 
22 Os. FEATURE: 
223 OTHER INFORMATION: 
oligonucleotide 
<4 OOs, SEQUENCE: 12 
CatCaC catc acCatCacta aa 
<210s, SEQ ID NO 13 
&211s LENGTH: 238 
212. TYPE: PRT 
<213> ORGANISM: Aquorea 
<4 OOs, SEQUENCE: 13 
Met Ser Lys Gly Glu Glu 
1. 5 
Glu Lieu. Asp Gly Asp Wall 
2O 
Gly Glu Gly Asp Ala Thr 
35 
Thir Thr Gly Lys Lieu Pro 
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29 
- Continued 
cticagg to aacaaccaca tdcacttcaa gag togc.catc 54 O 
gtggat.cc atgttcacct acagaaaggit taggagctic 6OO 
ttgttgag taccago atgtc.ttcaaaac tocaactgct 660 
666 
al Sequence 
Description of Artificial Sequence: Synthetic 
tcqcagtic gg tactiv 37 
al Sequence 
Description of Artificial Sequence: Synthetic 
agcagtgg tat caacgca gagt 44 
al Sequence 
Description of Artificial Sequence: Synthetic 
t catg 27 
al Sequence 
Description of Artificial Sequence: Synthetic 
22 
victoria 
Lieu. Phe Thr Gly Val Val Pro Ile Leu Val 
1O 15 
Asn Gly His Llys Phe Ser Val Ser Gly Glu 
25 3O 
Tyr Gly Llys Lieu. Thir Lieu Lys Phe Ile Cys 
4 O 45 































































<210 SEQ ID NO 14 
&211s LENGTH: 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 
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- Continued 
Arg Arg Val Glu Glu Thir His Thir Lys Glu Asn Lieu Ala Met Val Glu 
195 2OO 2O5 
Tyr Glin Glin Val Phe Asn Ser Ala Pro Arg Asp Met 
21 O 215 22O 
<210s, SEQ ID NO 15 
&211s LENGTH: 222 
212. TYPE: PRT 
<213> ORGANISM; Labidocera aestiva 
<4 OOs, SEQUENCE: 15 
Met Pro Val Met Lys Ile Glu. Cys Arg Ile Ser Gly Thr Met Asin Gly 
1. 5 1O 15 
Glu Glu Phe Glu Lieu Val Gly Ala Gly Asp Gly Asn. Thir Asp Glu Gly 
2O 25 3O 
Arg Met Thr Asn Lys Met Lys Ser Thr Lys Gly Pro Leu Ser Phe Ser 
35 4 O 45 
Pro Tyr Lieu. Leu Ser His Ile Met Gly Tyr Gly Phe Tyr His Tyr Ala 
SO 55 6 O 
Thir Phe Pro Ala Gly Tyr Glu Asn Val Tyr Lieu. His Ala Ala Lys Asn 
65 70 7s 8O 
Gly Gly Tyr Thr Asn Thr Arg Thr Glu Arg Tyr Glu Asp Gly Gly Ile 
85 90 95 
Ile Ser Val Asin Phe Thr Tyr Arg Tyr Glu Gly Asn Llys Val Ile Gly 
1OO 105 11 O 
Asp Phe Llys Val Val Gly Ser Gly Phe Pro Ala Asn Ser Val Ile Phe 
115 120 125 
Thr Asp Lys Ile Ile Llys Ser Asn Pro Thr Cys Glu. His Ile Tyr Pro 
13 O 135 14 O 
Lys Gly Asp Asn. Ile Lieu Val Asn Ala Tyr Thr Arg Thir Trp Met Lieu. 
145 150 155 160 
Arg Asp Gly Gly Tyr Tyr Ser Ala Glin Val Asn. Asn His Lieu. His Phe 
1.65 17O 17s 
Lys Thr Ala Met His Pro Thr Met Leu Glin Asn Gly Gly Ser Met Phe 
18O 185 19 O 
Thir Tyr Arg Llys Val Glu Glu Lieu. His Ser Glin Ser Asp Val Gly Ile 
195 2OO 2O5 
Val Glu Tyr Gln His Val Phe Llys Thr Pro Thr Ala Phe Ala 
21 O 215 22O 
<210s, SEQ ID NO 16 
&211s LENGTH: 222 
212. TYPE: PRT 
<213> ORGANISM: unidentified Pontella 
<4 OOs, SEQUENCE: 16 
Met Ala Ala Met Lys Ile Glu. Cys Arg Ile Thr Gly Thr Met Asin Gly 
1. 5 1O 15 
Val Glu Phe Glu Lieu Val Gly Gly Gly Glu Gly Asn. Thir Asp Glin Gly 
2O 25 3O 
Arg Met Thr Asn Lys Met Lys Ser Thr Lys Gly Pro Leu Ser Phe Ser 
35 4 O 45 
Pro Tyr Lieu. Leu Ser His Val Met Gly Tyr Gly Phe Tyr His Phe Gly 
SO 55 6 O 
Thr Phe Pro Ser Gly Tyr Glu Asn Pro Tyr Val His Ala Met Thr Asn 












































<210s, SEQ ID NO 17 
&211s LENGTH: 222 
212. TYPE : 
&213s ORGANISM: 
PRT 
<4 OOs, SEQUENCE: 17 
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37 
- Continued 
&211s LENGTH: 222 
212. TYPE: PRT 
<213> ORGANISM: Plantago meadi 
<4 OOs, SEQUENCE: 18 
Met Pro Asp Met Lys Lieu. Glu. Cys His Ile Ser Gly Thr Met Asin Gly 
1. 5 1O 15 
Glu Glu Phe Glu Lieu. Ile Gly Ser Gly Asp Gly Asn. Thir Asp Glin Gly 
2O 25 3O 
Arg Met Thr Asn Asn Met Lys Ser Ile Lys Gly Pro Leu Ser Phe Ser 
35 4 O 45 
Pro Tyr Lieu. Leu Ser His Ile Leu Gly Tyr Gly Tyr Tyr His Phe Ala 
SO 55 6 O 
Thr Phe Pro Ala Gly Tyr Glu Asn Ile Tyr Lieu. His Ala Met Lys Asn 
65 70 7s 8O 
Gly Gly Tyr Ser Asn Val Arg Thr Glu Arg Tyr Glu Asp Gly Gly Ile 
85 90 95 
Ile Ser Ile Thr Phe Asn Tyr Arg Tyr Glu Gly Ser Lys Ile Ile Gly 
1OO 105 11 O 
Asp Phe Llys Val Ile Gly Thr Gly Phe Pro Thr Asp Ser Lieu. Ile Phe 
115 12 O 125 
Thr Asp Lys Ile Ile Llys Ser Asn Pro Thr Cys Glu Asn Met Phe Pro 
13 O 135 14 O 
Lys Ala Asp Asn. Ile Lieu Val Asn Ala Tyr Thr Arg Thr Tyr Lieu. Lieu. 
145 150 155 160 
Lys Asp Gly Gly Tyr Tyr Ser Ala Glin Val ASn Asn His Met His Phe 
1.65 17O 17s 
Lys Ser Ala Ile His Pro Thr Met Leu Glin Asn Gly Gly Ser Met Phe 
18O 185 19 O 
Thr His Arg Val Val Glu Glu Asn His Thr Lys Thr Asn Val Ala Ile 
195 2OO 2O5 
Val Glu Tyr Glin Asn Val Phe Llys Thr Pro Thr Ala Phe Ala 
21 O 215 22O 
<210s, SEQ ID NO 19 
&211s LENGTH: 222 
212. TYPE: PRT 
<213> ORGANISM: Pseudopontella plumata 
<4 OOs, SEQUENCE: 19 
Met Pro Ala Met Lys Ile Glu. Cys Arg Ile Ser Gly Thr Lieu. Asn Gly 
1. 5 1O 15 
Val Val Phe Glu Lieu Val Gly Gly Gly Glu Gly Ile Pro Glu Glin Gly 
2O 25 3O 
Arg Met Thr Asn Lys Met Lys Ser Thr Lys Gly Ala Lieu. Thr Phe Ser 
35 4 O 45 
Pro Tyr Lieu. Leu Ser His Val Met Gly Tyr Gly Phe Tyr His Phe Gly 
SO 55 6 O 
Thr Tyr Pro Ser Gly Tyr Glu Asn Pro Phe Lieu. His Ala Ala Asn Asn 
65 70 7s 8O 
Gly Gly Tyr Thr Asn. Thir Arg Ile Glu Lys Tyr Glu Asp Gly Gly Val 
85 90 95 
Lieu. His Val Ser Phe Ser Tyr Arg Tyr Glu Ala Gly Arg Val Ile Gly 
1OO 105 11 O 
Asp Phe Llys Val Val Gly Thr Gly Phe Pro Glu Asp Ser Val Ile Phe 
115 12 O 125 
38 
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- Continued 









Wall Wall Phe Ala 
155 
Lell Ser Thir 
150 
Gly Asp Asn Gly Arg 
Phe Wal Wall 
17O 





Ile Lieu. Glin Asn 
185 
Ser His Pro Ser Gly Gly 
Ala Phe Wall Glu Glu Thir Glu Lieu. His Ser Asn Arg 
195 
Arg 
Wall Glin Ala Phe 
215 
Thir Thir Ala Glu Tyr His Pro Phe 
21 O 
<210s, SEQ ID NO 2 O 
&211s LENGTH: 222 
212. TYPE: PRT 
<213> ORGANISM: Pseudopontella plumata 
<4 OOs, SEQUENCE: 2O 
Met Pro Ala Met 
1. 
Ile Glu Ile Lys Thir Thir 
5 
Arg Gly 














Pro Tyr Lieu Lieu Ser His 
SO 
Gly Tyr Gly 
Thir 
65 
Glu Phe Lieu. His Ala Pro Ser Gly Tyr Asn. Pro 
70 
Gly Gly Thir ASn. Thir Ile Glu Glu 
85 
Tyr Arg Lys 
90 
Asp 
Wall Ser Phe Ser Glu Ala Lieu. His Arg Tyr 
105 
Gly Arg 
Phe Wall Wall Thir Phe Glu Ser 
125 





Thir Ile Ile Ala Thir Wall Glu 
14 O 







Wall Wall Phe Ala 
155 
Gly Lell Ser Thir 
150 
Asp Asn Gly Arg 
Phe Wal Wall 
17O 





Ile Lieu. Glin Asn 
185 
Ser His Pro Ser Gly Gly 





Glin Ala Phe 
215 
Thir Ile Ala Tyr His Pro Phe 
The invention claimed is: 
1. An isolated protein molecule comprising an amino acid 
sequence, wherein the amino acid sequence is at least 96% 
identical to the amino acid sequence of SEQ ID NO: 1 or 
wherein the amino acid sequence is encoded by a nucleic acid 
sequence that is at least 96% identical to the nucleic acid 
sequence of SEQID NO: 2, and wherein the isolated protein 





















































2. The protein molecule of claim 1, wherein the protein 
molecule has a molar extinction coefficient of at least 100,000 
Mcm. 
3. The protein molecule of claim 1, wherein the protein 
molecule has a quantum yield of at least 0.90. 
4. The protein molecule of claim 1, wherein the amino acid 
sequence is at least 97.98 or 99% identical to the amino acid 
sequence of SEQ ID NO: 1 or wherein the amino acid 
US 8,772,454 B2 
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sequence is encoded by a nucleic acid sequence that is at least 
97, 98 or 99% identical to the nucleic acid sequence of SEQ 
ID NO: 2. 
5. The protein molecule of claim 1, wherein the protein 
molecule has an absorbance maximum between 480-490 nm. 
and an emission maximum between 500-511 nm. 
6. The protein molecule of claim 1, wherein the protein 
molecule comprises the amino acid sequence of SEQID NO: 
1 and is isolated from Pontella mimocerami. 
7. A purified green fluorescent protein produced by 
ligating one or more amplified nucleic acids encoding a 
green fluorescent protein into a vector, wherein said one 
or more amplified nucleic acids have a nucleotide 
sequence with at least 96% sequence identity to the 
nucleotide sequence of SEQID NO: 2, and wherein the 
encoded green fluorescent protein has green fluorescent 
protein activity; 
transfecting a host cell with the vector; 
expressing the green fluorescent protein in the host cell; 
and 
purifying the green fluorescent protein from the host cell. 
8. An isolated green fluorescent protein isolated by 
transfecting one or more cells with a nucleic acid encoding 
a green fluorescent protein, wherein said nucleic acid 
has a nucleotide sequence with at least 96% sequence 
identity to the nucleotide sequence of SEQID NO: 2 and 
wherein the green fluorescent protein has green fluores 






plating the one or more cells onto a culture plate; 
incubating the culture plate at 37°C. for a period not less 
than 8 hours, to express said green fluorescent protein in 
the one or more cells and form one or more green fluo 
rescent colonies; 
selecting and picking at least one of the one or more green 
fluorescent colonies from the culture plate to form 
Selected green fluorescent colonies; 
resuspending the selected green fluorescent colonies in 
water or a buffer to form resuspended green fluorescent 
colonies; 
plating the resuspended green fluorescent colonies onto a 
second culture plate; 
incubating the second culture plate at room temperature for 
at least 48 hours to form green fluorescent colonies; 
resuspending the green fluorescent colonies in the buffer; 
Sonicating the green fluorescent colonies in the buffer on 
ice to form a sonicated buffer solution; 
centrifuging the Sonicated buffer Solution; 
separating the Sonicated buffer Solution to yield a lysate 
and a cellular debris; and 
isolating said green fluorescent protein from the lysate, the 
cellular debris or both using metal-affinity chromatog 
raphy, chromatography, affinity extraction, or other pro 
tein purification techniques. 
9. Akit comprising one or more containers, wherein at least 
one of the one or more containers comprises an isolated 
protein molecule comprising an amino acid sequence, 
wherein the amino acid sequence is at least 96% identical to 
the amino acid sequence of SEQID NO: 1, and wherein the 
isolated protein molecule has green fluorescent protein activ 
